Department of Pediatric Cardiology, Ministry of Health, Ankara City Hospital, Ankara, Turkey.
Department of Pediatric Cardiology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
Cardiol Young. 2021 May;31(5):817-821. doi: 10.1017/S1047951120004746. Epub 2021 Jan 7.
Vasovagal syncope is the most common cause of syncope in childhood and its treatment is not at a satisfactory level yet. We aimed to investigate patients who were diagnosed with vasovagal syncope, did not benefit from conventional treatment, received midodrine treatment, and to evaluate their response to midodrine treatment.
Files of 24 patients who were diagnosed with recurrent vasovagal syncope, did not benefit from non-pharmacological treatments, and received midodrine treatment during June 2017-October 2019 were retrospectively analysed.
In total, 24 patients received a treatment dose of midodrine at 5 mg/day (2.5 mg BID) included in the study. The mean number of syncope was 5.75 ± 2.67 prior to treatment. Following treatment, the mean number of syncope was 0.42 ± 0.89. It was observed that syncope episodes did not recur in 17 patients, but it recurred in 4 out of 7 patients in the first 3 months of the treatment and did not recur in the following months. The episodes improved in two patients with an increase in the treatment dose, but the syncope episodes continued in only one patient.
It was concluded that midodrine treatment was effective and safe in adolescents with recurrent vasovagal syncope.
血管迷走性晕厥是儿童晕厥最常见的原因，其治疗效果尚未达到令人满意的水平。我们旨在研究诊断为血管迷走性晕厥、常规治疗无效、接受米多君治疗的患者，并评估其对米多君治疗的反应。
回顾性分析 2017 年 6 月至 2019 年 10 月期间诊断为复发性血管迷走性晕厥、非药物治疗无效且接受米多君治疗的 24 例患者的档案。
共有 24 例患者接受了米多君治疗，治疗剂量为 5mg/天（bid，每次 2.5mg）。治疗前晕厥平均次数为 5.75±2.67 次。治疗后，晕厥平均次数为 0.42±0.89 次。17 例患者无晕厥发作复发，但 7 例患者中有 4 例在治疗的前 3 个月复发，随后几个月无复发。在增加治疗剂量后，有 2 例患者的发作得到改善，但仅有 1 例患者的晕厥发作持续存在。
米多君治疗青少年复发性血管迷走性晕厥是有效且安全的。
